SIGA TECHNOLOGIES (SIGA) Company Report

For the nine months ended September 30, 2025, SIGA reported product revenue of approximately $86 million, including $53 million from oral TPOXX and $26 million from IV TPOXX sales under the BARDA contract, and $6 million from international oral TPOXX sales. The company recorded a net loss of approximately $6 million for Q3 2025, following a strong Q2 2025 with $79 million in product revenues.
As of September 30, 2025, SIGA maintained a strong cash balance of approximately $172 million with no debt. Since 2020, the company has returned approximately $230 million to shareholders through dividends and share buybacks.
There is $26 million in outstanding U.S. government orders for IV TPOXX, expected for delivery in 2026. SIGA anticipates multiple international sales in 2026 based on ongoing discussions and interest from key stakeholders.
The company is targeting an FDA submission for the TPOXX post-exposure prophylaxis (PEP) indication in 2026 and an IND submission for its pediatric program by year-end 2025. SIGA continues to engage with the U.S. government regarding future TPOXX procurement, despite potential delays due to the government shutdown.

Nov 6, 2025, 9:30 PM

SIGA Technologies Reports Q3 2025 Financial Results and Business Updates

SIGA

Earnings

Dividends

New Projects/Investments

SIGA Technologies reported $90.8 million in total revenues and $28.7 million in net income for the nine months ended September 30, 2025, compared to $57.3 million and $13.5 million, respectively, for the same period in 2024. For the third quarter of 2025, the company recorded a net loss of $6.4 million and diluted loss per share of $(0.09) on total revenues of $2.6 million.
For the first nine months of 2025, the company generated $53 million from oral TPOXX and $26 million from IV TPOXX deliveries to the U.S. Strategic National Stockpile, and received a $26 million procurement order for IV TPOXX from the U.S. Government in March 2025.
The BARDA 19C contract was modified in Q2 2025 to add $27 million in development funding for TPOXX pediatric development and manufacturing activities.
In January 2025, TPOXX received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, and complications following smallpox vaccination. Additionally, a special cash dividend of $0.60 per share was declared on April 8, 2025, and paid on May 15, 2025.

Nov 6, 2025, 9:06 PM

SIGMA Corp. Partner KRTL Biotech Highlights Anti-Infectives and Antibiotics Portfolio

SIGA

Product Launch

New Projects/Investments

KRTL Biotech, a majority-owned subsidiary of KRTL Holding Group Inc., is highlighting its expanded portfolio of anti-infective and antibiotic products, developed in collaboration with SIGMA Corp..
The current product line includes essential formulations such as Hostess Suspension, Positrin, and Taxonid, with SIGMA's GMP-certified facility capable of producing a broader range of therapies, including penicillin derivatives and macrolides.
These offerings align with the World Health Organization's (WHO) Model List of Essential Medicines, targeting a global anti-infectives market estimated to exceed $150 billion annually.
KRTL Biotech is evaluating regulatory pathways for select formulations to enter U.S. and other export markets, leveraging SIGMA's manufacturing capabilities in Bolivia, which contributed significantly to national pharmaceutical distribution in fiscal year 2024.